Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Zhejiang Huakang Pharmaceutical Co., Ltd. specializes in the production of active pharmaceutical ingredients (APIs) and intermediates, primarily serving the Chinese and international markets. The company differentiates itself through its focus on high-quality manufacturing processes and a diverse product portfolio that includes cardiovascular and anti-infective drugs.
Zhejiang Huakang generates revenue by producing and selling APIs to pharmaceutical companies, leveraging its established relationships and regulatory compliance to maintain pricing power. The company benefits from economies of scale in production, allowing it to reduce costs and improve margins.
Changes in regulatory approvals for new APIs
Fluctuations in raw material costs, particularly for key chemicals
Market demand for cardiovascular and anti-infective drugs
Currency exchange rates impacting export revenues
Regulatory changes affecting the pharmaceutical industry
Technological advancements in drug development that could render existing products obsolete
Increased competition from generic drug manufacturers
Potential entry of multinational pharmaceutical companies into the Chinese market
High debt-to-equity ratio (1.16) indicating potential liquidity concerns
Negative free cash flow could limit operational flexibility
moderate - The pharmaceutical sector is somewhat insulated from economic downturns, but demand for non-essential drugs can decline during recessions.
Interest rates affect the company's financing costs for capital expenditures and can influence demand for pharmaceuticals as consumer spending tightens.
minimal - The company is not heavily reliant on credit markets for its operations.
value - Investors may be drawn to the stock due to its low price-to-sales ratio (0.7x) and potential for recovery as margins improve.
high - The stock has exhibited significant volatility, with a 1-year return of -32.7%.
